Ascent Group LLC Cuts Stock Holdings in Boston Scientific Corporation $BSX

Ascent Group LLC lowered its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 9.6% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 45,148 shares of the medical equipment provider’s stock after selling 4,794 shares during the quarter. Ascent Group LLC’s holdings in Boston Scientific were worth $4,849,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also modified their holdings of the company. 1248 Management LLC purchased a new stake in shares of Boston Scientific during the 1st quarter worth $26,000. Y.D. More Investments Ltd purchased a new stake in shares of Boston Scientific during the 1st quarter worth $27,000. Sound Income Strategies LLC lifted its position in shares of Boston Scientific by 90.9% during the 2nd quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 120 shares during the last quarter. Oliver Lagore Vanvalin Investment Group purchased a new stake in shares of Boston Scientific during the 2nd quarter worth $37,000. Finally, Activest Wealth Management lifted its position in shares of Boston Scientific by 6,216.7% during the 1st quarter. Activest Wealth Management now owns 379 shares of the medical equipment provider’s stock worth $38,000 after purchasing an additional 373 shares during the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Insider Buying and Selling

In other news, EVP Arthur C. Butcher sold 17,313 shares of the business’s stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $104.63, for a total transaction of $1,811,459.19. Following the transaction, the executive vice president directly owned 23,600 shares in the company, valued at $2,469,268. The trade was a 42.32% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Yoshiaki Fujimori sold 2,901 shares of the business’s stock in a transaction dated Tuesday, July 29th. The stock was sold at an average price of $106.99, for a total transaction of $310,377.99. Following the transaction, the director owned 2,081 shares in the company, valued at approximately $222,646.19. This trade represents a 58.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 174,214 shares of company stock worth $17,972,457. Corporate insiders own 0.50% of the company’s stock.

Boston Scientific Price Performance

Shares of BSX opened at $97.30 on Friday. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37. Boston Scientific Corporation has a fifty-two week low of $80.64 and a fifty-two week high of $109.50. The firm has a 50-day simple moving average of $102.93 and a 200-day simple moving average of $102.05. The company has a market capitalization of $144.17 billion, a price-to-earnings ratio of 57.91, a price-to-earnings-growth ratio of 2.32 and a beta of 0.61.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.72 by $0.03. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The firm had revenue of $5.06 billion for the quarter, compared to analyst estimates of $4.89 billion. During the same quarter last year, the company posted $0.62 earnings per share. The business’s revenue was up 22.8% on a year-over-year basis. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, equities research analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Analyst Ratings Changes

Several research firms have recently issued reports on BSX. Wells Fargo & Company lifted their price objective on shares of Boston Scientific from $118.00 to $124.00 and gave the stock an “overweight” rating in a research report on Thursday, July 24th. Oppenheimer raised shares of Boston Scientific from a “market perform” rating to an “outperform” rating and lifted their price objective for the stock from $118.00 to $125.00 in a research report on Monday, September 8th. Royal Bank Of Canada reiterated an “outperform” rating and set a $125.00 price target on shares of Boston Scientific in a research note on Monday, September 29th. Leerink Partners boosted their price target on shares of Boston Scientific from $127.00 to $128.00 and gave the company an “outperform” rating in a research report on Wednesday. Finally, Weiss Ratings reissued a “buy (b-)” rating on shares of Boston Scientific in a research report on Saturday, September 27th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, Boston Scientific has an average rating of “Buy” and a consensus price target of $120.79.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.